STOK

26.6401.08%
JH

Jason Hoitt

Chief Patient Officer

Mr. Jason Hoitt was Chief Commercial Officer of Stoke Therapeutics, Inc. from April 2024 until June 2025 and serves as its Chief Patient Officer since June 2025. Mr. Hoitt had been the Chief Commercial Officer at Provention Bio, Inc., since joining it January 2020. Mr. Hoitt is responsible for the development and execution of Provention's global commercial strategy for PRV-031 (teplizumab). Mr. Hoitt served as Chief Commercial Officer at Dova Pharmaceuticals Inc. since December 2018 until November 12, 2019 and led all commercial efforts including the pre-launch and launch strategy and execution for DOPTELET® (avatrombopag) targeting chronic immune thrombocytopenia. Prior to Dova, he was the Vice President and Head of US Sales at Insmed Inc. from May 2017 to December 2018, serving as a Vice President and Head of Sales for the launch of Arikayce and served as its Member of the commercial leadership team. Prior to joining Insmed, he spent four years at Sarepta Therapeutics from October 2013 to May 2017, where he held leadership roles in Medical Affairs and US Sales and launched EXONDYS 51. Previously, he held senior positions in both marketing and sales at Vertex Pharmaceuticals, where he played an integral role in launching Incivek. From 2004 to 2010, he was at Gilead Sciences in a variety of roles of increasing responsibility, culminating in a lead role in the launch of Viread for HBV. He began his career as a bench researcher at Boston’s New England Medical Center, (Tufts Medical School), which led to biopharmaceutical roles at AstraZeneca and Schering Oncology-Biotech. He has commercial experience in the biotechnology sector. Mr. Hoitt holds a B.A. from the College of the Holy Cross in Worcester, MA.

公司职务